Abstract：【Objective】To investigate the efficacy of Anlotinib in the treatment of patients with advanced non-small cell lung cancer (NSCLC) and its influence on quality of life. 【Methods】A total of 98 patients with advanced NSCLC treated in our hospital from August 2022 to August 2024 were selected and divided into control group (given conventional chemotherapy) and observation group (given Anlotinib on the basis of conventional chemotherapy) according to different treatment methods, with 49 cases in each group. The clinical efficacy, serum indexes, quality of life and incidence of adverse reactions were compared between the two groups. 【Results】The disease control rate and overall response rate of the observation group were higher than those of the control group (P<0.05). After treatment, the levels of vascular endothelial growth factor (VEGF), carbohydrate antigen 125 (CA125) and matrix metalloproteinase-9 (MMP-9) in the observation group were lower than those in the control group (P<0.05). After treatment, the score of Generic Quality of Life Inventory (GQOLI-74) in the observation group was higher than that in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the observation group and the control group (P>0.05). 【Conclusion】Anlotinib combined with conventional chemotherapy has significant efficacy in the treatment of patients with advanced NSCLC, which can significantly improve the quality of life of patients, significantly down-regulate the levels of biomarkers related to tumor angiogenesis, invasion and metastasis, and has good safety.
王潇, 陈高瑛, 尚艳. 安罗替尼治疗晚期非小细胞肺癌患者的疗效及对患者生活质量的影响*[J]. 医学临床研究, 2025, 42(6): 920-922.
WANG Xiao, CHEN Gaoying, SHANG Yan. Efficacy of Anlotinib in the Treatment of Advanced Non-Small Cell Lung Cancer and its Influence on Quality of Life. JOURNAL OF CLINICAL RESEARCH, 2025, 42(6): 920-922.
2025, Vol. 42 
